The Food and Drug Administration (FDA) had approved ICIs inhibitors for the treatment of many cancer types including HCC, comprising nivolumab (antibody against PD-1), and a combination of atezolizumab (antibody against PD-L1) and bevacizumab (anti-vascular endothelial growth factor/anti-VEGF) [4,5]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.